1.Correlation between patients with coronary heart disease and the level of high-sensitivity C-reactive protein and brain natriuretic peptide and adiponectin level
Yong-Jun LIN ; Chun-Fang WU ; Zhi-Rong YE ; Da-Jun CHAI
The Chinese Journal of Clinical Pharmacology 2017;33(5):463-466
Objective To study the effect of high-sensitivity C-reactive protein(hs-CRP),brain natriuretic peptide (BNP),adiponectin (APN) on coronary heart disease(CHD) occurrence,clinical course and prognosis,as well as the correlation among different types of coronary heart disease.Methods A total of 528 cases were divided into control group (same period of healthy volunteers) with 250 cases and the treatment group (CHD patients) with 278 cases,and the treatment group was divided into three groups according to clinical types of coronary heart disease:acute myocardial infarction (AMI) group with 40 cases,unstable angina pectoris (UPA) group with 121 cases,stable angina pectoris (SAP) group with 117 cases.In treatment group,the serum hs-CRP concentration were detected by latex immune ratio;and the serum BNP concentration was determined by chemiluminescence microparticle immuno assay;the serum APN concentration was measured by ELISA.Results In control group and treatment group,the serum hs-CRP were (3.78 ±2.12),(7.29 ±5.98) mg · L-1,the difference was statistically significant (P < 0.05);the serum APN content division ratio of (81.21 ± 20.89),(1423.89 ± 1389.21) pg · mL-1,the difference was statistically significant (P <0.05);the serum BNP levels were (929.23 ± 312.67),(412.34 ±299.89) μg · mL-1,the difference was statistically significant (P <0.05).In the treatment group of coronary heart disease,hs-CRP concentration and BNP were not correlated,the difference was not statistically significant (P > 0.05).There was a negative correlation (r =-0.567) and a statistically significant (P <0.05) between hs-CRP and APN.No correlation and no significant difference were found between BNP and APN (P > 0.05).Conclusion The serum hs-CRP,APN and BNP levels were closely related to the development of coronary heart disease,thus they are considered as risk factors for coronary heart disease.
2.Impact of acute glucose and fat loading on endothelium dependent vasodilation in patients with essential hypertension
Xiao-Rong ZHENG ; Da-Jun CHAI ; Feng PENG ; Jun-Xia XU ; Jin-Xiu LIN
Chinese Journal of Cardiology 2010;38(12):1085-1088
Objective To explore the influence of acute glucose and fat loading on endothelium dependent flow-mediated vasodilation (FMD) in patients with essential hypertension (EH). Methods Patients with EH were randomly divided into three groups: oral glucose loading alone (n = 26 ), oral standardized fat loading alone (n = 38), combined glucose and fat loading (n = 34 ). FMD of the brachial artery was assessed by high resolution ultrasound technique respectively. Results ( 1 ) Compared to control group, postrandial abnomal serum triglyceride metabolism was evidenced and FMD was significantly reduced and the lowest FMD occurred at 4 hours and returned to the baseline level at 8 hours post fat loading alone in EH patients. (2) GS-AUC and 1 hour glucose were significantly higher in EH patients than in controls (all P <0. 05), FMD was also significant decreased ( -31.4% ) at 1 hour and returned to baseline level at 2 hours post oral glucose loading. ( 3 ) After combined glucose and fat loading, FMD at 1 hour ( 5.45 ± 1.93 vs. 9.46 ± 3.33, P < 0.05 ) was significantly lower than that in glucose loading alone and FMD at 4 hours ( 7. 98 ± 1. 64 vs. 9. 66 ± 2. 26, P < 0. 05 ), was also lower than that in fat loading alone in EH patients.(4) FMD was negatively correlated with SBP, GS-AUC, DBP, TG-AUC ( γ= - 0. 46, - 0. 44, - 0. 41,- 0. 38,respectively, all P < 0. 05 ). Conclusion Combined glucose and fat loading additively reduced FMD in hypertensive patients.
3.Association between high sensitivity C-reactive protein and contrast induced acute kidney Injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin
Jin-Zi SU ; Yan XUE ; Wen-Qin CAI ; Qun-Ying HUANG ; Da-Jun CHAI ; Guang-Ling CHEN ; Fang-Bing WANG ; Xiu-Ping CHEN ; Du-Sheng ZHANG
Chinese Journal of Cardiology 2011;39(9):807-811
Objective To observe the association between preprocedural high sensitivity C-reactive protein (hs-CRP) level and incidence of contrast induced acute kidney injury (CI-AKI) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and the impact of atorvastatin pretreatment on CI-AKI. Methods According to the level of preprocedural hs-CRP, 270 ACS patients were divided into three groups: high hs-CRP group (hs-CRP≥3 mg/L, n =176), moderate hsCRP group (hs-CRP 1 -3 mg/L, n =60) and normal hs-CRP group ( hs-CRP < 1 mg/L, n =34).According to the dosage of preprocedural atorvastatin, the high hs-CRP group was further divided into 10 mg group (n =49), 20 mg group (n =66) and 40 mg group (n =61 ). Serum creatinine (Ser), blood urea nitrogen (BUN), cystatin C (Cys C), hs-CRP were measured at before and 24 hours, 48 hours after PCI.CCr and GFR were calculated according to Scr and Cys C. Risk factors for CI-AKI were determined by multivariate logistic regression analysis. Results ( 1 ) Cys C was significantly increased and GFR after PCI significantly reduced in high and moderate hs-CRP groups compared with normal hs-CRP group ( P < 0. 05 ).(2) Incidence of CI-AKI was 43. 18%, 38. 33% , 20. 59% in high, moderate and normal hs-CRP groups,respectively (P < 0. 05 ). (3) In high hs-CRP group, postprocedural GFR was significantly higher while postprocedural Cys C and hs-CRP were significantly lower in 40 mg statin subgroup than 10 mg and 20 mg statin subgroups (P < 0. 05), similar trends were documented when comparing 20 mg statin subgroup with 10 mg statin subgroup ( P < 0. 05 ). (4) Multivariate logistic regression analysis showed that pretreatment with high dose atorvastatin was a protective factor for post CI-AKI (20 mg atorvastatin: OR =0. 15, 95% CI 0. 06 -0. 33, P =0. 00 1 ; 40 mg atorvastatin: OR =0. 10, 95 % CI 0. 04 -0. 23, P =0. 001 ), while high levels of preprocedural hs-CRP (OR =2. 06, 95% CI 1.01 -4. 23, P =0. 048), diabetes mellitus (OR =10.71,95% CI5.29 -21.70, P=0.001), advanced age (OR =2. 64, 95% CI 1.05 -6. 63, P =0.038)and renal failure ( OR =5. 14, 95% CI 1.13 - 23.39, P =0. 034 ) were independent risk factors of CIAKI. Conclusion High hs-CRP level is linked with the development of CI-AKI in ACS patients undergoing PCI and pretreatment with 40 mg atorvastatin is associated with lower incidence CI-AKI, possibly by reducing the postprocedural inflammation responses.
4.Expert consensus on recombinant B subunit/inactivated whole-cell cholera vaccine in preventing infectious diarrhea of enterotoxigenic Escherichia coli
Chai JI ; Yu HU ; Mingyan LI ; Yan LIU ; Yuyang XU ; Hua YU ; Jianyong SHEN ; Jingan LOU ; Wei ZHOU ; Jie HU ; Zhiying YIN ; Jingjiao WEI ; Junfen LIN ; Zhenyu SHEN ; Ziping MIAO ; Baodong LI ; Jiabing WU ; Xiaoyuan LI ; Hongmei XU ; Jianming OU ; Qi LI ; Jun XIANG ; Chen DONG ; Haihua YI ; Changjun BAO ; Shicheng GUO ; Shaohong YAN ; Lili LIU ; Zengqiang KOU ; Shaoying CHANG ; Shaobai ZHANG ; Xiang GUO ; Xiaoping ZHU ; Ying ZHANG ; Bangmao WANG ; Shuguang CAO ; Peisheng WANG ; Zhixian ZHAO ; Da WANG ; Enfu CHEN
Chinese Journal of Clinical Infectious Diseases 2023;16(6):420-426
Enterotoxigenic Escherichia coli(ETEC)infection can induce watery diarrhea,leading to dehydration,electrolyte disturbance,and even death in severe cases. Recombinant B subunit/inactivated whole-cell cholera(rBS/WC)vaccine is effective in preventing ETEC infectious diarrhea. On the basis of the latest evidence on etiology and epidemiology of ETEC,as well as the effectiveness,safety,and health economics of rBS/WC vaccine,National Clinical Research Center for Child Health(The Children’s Hospital,Zhejiang University School of Medicine)and Zhejiang Provincial Center for Disease Control and Prevention invited experts to develop expert consensus on rBS/WC vaccine in prevention of ETEC infectious diarrhea. It aims to provide the clinicians and vaccination professionals with guidelines on using rBS/WC vaccine to reduce the incidence of ETEC infectious diarrhea.